#USA #Boston #Medicilon #Revolution Medicines #Kras Drug Development

Celebrating Excellence in Collaboration: Medicilon Awards Revolution Medicines

On October 30, 2026, Medicilon presented the prestigious 'Excellence in Client Partnership Award' to Revolution Medicines, a gesture underscoring the fruitful collaboration between the two entities. This award was presented during a visit by esteemed professionals from Revolution Medicines, including Dr. Yang Liu, the Director of Medicinal Chemistry, and Dr. Kristof Pota, a Senior Scientist. Their visit to Medicilon’s Nanhui R&D center marked a significant milestone in their ongoing partnership.

A Partnership Built on Trust

Over the past three years, the collaboration between Medicilon and Revolution Medicines has thrived through a model centered on trust and mutual respect. The partnership has consistently focused on addressing complex R&D challenges while prioritizing client needs and ensuring the efficient delivery of high-quality drug molecules. This positive relationship has laid the groundwork for exceptional synergy between the client and the contract research organization (CRO).

During the award ceremony, Dr. Maosheng Duan, General Manager of Medicilon's Drug Discovery and Pharmaceutical Research Divisions, praised the groundbreaking achievements of Revolution Medicines in advancing KRAS, a target previously deemed 'undruggable.' He highlighted the recent approval by the FDA of the new drug application (NDA) for Daraxonrasib, a significant breakthrough for treating metastatic pancreatic cancer. This approval offers renewed hope to patients battling this aggressive form of cancer and adds substantial clinical value to their research and development efforts.

The Excellence in Client Partnership Award not only celebrates the mutual accomplishments of the teams over the last three years but also reflects Medicilon's confidence in fostering a deeper and more enduring alliance with Revolution Medicines.

In-depth Discussions for Future Collaborations

As part of the visit, a detailed discussion was held regarding new collaborative opportunities. Dr. Jian Wang, Vice President of Medicilon, elaborated on the firm's growth and its integrated R&D platform that spans from therapeutic target discovery to new drug application submissions. Medicilon's quality system adheres to international standards and boasts numerous accreditations, including NMPA, OECD GLP, FDA GLP, and AAALAC. Their advanced platforms support a wide range of programs, including ADC/AOC, TPD, RIPTAC, RNA interference (RNAi), and peptides.

The talks also addressed critical aspects such as interregional data transfer, project management, future collaborations, and ways to enhance cross-border R&D efficiency, ensuring that both parties continue to thrive in their pursuits.

A Closer Look at Medicilon's Facilities

Following their discussions, Dr. Liu and Dr. Pota had the opportunity to tour Medicilon’s R&D laboratories, where they visited various specialized labs, including those focusing on chemistry and oligonucleotides, in addition to preclinical research facilities and active pharmaceutical ingredients (APIs). This onsite visit provided an insightful overview of Medicilon's R&D infrastructure and quality management systems, underscoring the effectiveness and capability of their operations.

In conclusion, the recognition bestowed upon Revolution Medicines illustrates the successful collaboration that has characterized their partnership with Medicilon. The path ahead appears bright, with both parties eager to build on their shared achievements and tackle the next challenges in the pharmaceutical landscape together.